Xolid 600mg Tablets – Broad-Spectrum Oxazolidinone Antibacterial Therapy

Product Overview

Xolid 600mg Tablets are a broad-spectrum synthetic oxazolidinone antibacterial formulation containing Linezolid (600mg). Designed for convenient oral administration, Xolid 600mg provides high systemic bioavailability, offering an oral alternative that is bioequivalent to intravenous therapy. It is indicated for the treatment of severe, complicated Gram-positive bacterial infections, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus faecium (VRE), hospital-acquired and community-acquired pneumonia, and complicated skin and skin structure infections (cSSSI).

Key Benefits

• Targeted Activity Against Multi-Drug Resistant Gram-Positives: Highly effective against resistant pathogens, including MRSA, VRE, and penicillin-resistant Streptococcus pneumoniae.

• 100% Oral Bioavailability: Delivers identical systemic blood concentrations via oral ingestion compared to intravenous administration, enabling seamless outpatient step-down care.

• Early-Stage Protein Synthesis Inhibition: Features a unique site of action that minimizes cross-resistance with other established antibiotic classes (e.g., beta-lactams, fluoroquinolones, macrolides).

• High Tissue Concentration: Achieves rapid penetration into lung, bone, muscle, and soft tissue structures.

• Convenient Twice-Daily Dosing: Simple 12-hour dosing regimen ensures consistent therapeutic tissue levels for fast infection resolution.

How It Works

Xolid 600mg Tablets (Linezolid) exert their antibacterial effect by selectively binding to the 23S ribosomal RNA of the 50S subunit on the bacterial ribosome. This action prevents the formation of the functional 70S initiation complex, which is essential for translating mRNA into vital bacterial proteins. By blocking protein synthesis at this early stage, Xolid halts bacterial growth, halts toxin production, and facilitates pathogen eradication by the host immune system.

Key Active Ingredients

• Linezolid (600mg per film-coated tablet): Synthetic oxazolidinone antibacterial agent that blocks bacterial 70S ribosomal initiation to treat resistant Gram-positive infections.

Directions for Use

1. Administration: Swallow the film-coated tablet whole with a full glass of water. Do not crush, chew, or split the tablet.

2. Timing: Take once every 12 hours (600mg twice daily), with or without food, as directed by your physician.

3. Treatment Duration: Complete the full course prescribed (typically 10 to 14 days; up to 28 days for VRE infections) to prevent bacterial recurrence or resistance.

Precautions

• Prescription-Only Medication: Administer strictly under the direction and supervision of a licensed healthcare provider.

• Reversible MAO Inhibition Warning: Linezolid is a reversible, non-selective Monoamine Oxidase (MAO) inhibitor. Avoid co-administration with serotonergic agents (e.g., SSRIs, SNRIs, tricyclic antidepressants) to avoid serotonin syndrome, and restrict consumption of tyramine-rich foods (e.g., aged cheeses, tap beers, soy sauce).

• Hematologic Monitoring: Reversible myelosuppression (anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported, particularly with courses exceeding 14 days. Monitor complete blood counts (CBC) weekly during prolonged therapy.

• Neuropathy Risk: Peripheral and optic neuropathy have been reported primarily in patients treated for longer than 28 days. Report any vision changes or numbness to a physician immediately.

• Consult a doctor before use during pregnancy or lactation.

• Keep out of reach of children.

Storage Instructions

Store in a cool, dry place below 30°C, protected from direct sunlight, excess heat, and moisture. Retain tablets in their original blister packaging until use.

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, dedicated to producing advanced anti-infective therapies that combat multi-drug resistant bacterial pathogens and improve patient health outcomes.